Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience
Cancer Medicine · 2026
DOI: 10.1002/cam4.71678 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Stefania Oliva und 37 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, High-Throughput Nucleotide Sequencing, Flow Cytometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health.
Abstract (Originalsprache)
Background
The level of measurable residual disease (MRD) is one of the most important features correlating depths of response and long‐term outcomes in multiple myeloma (MM) and MRD evaluation is currently the gold standard tool for assessing treatment response. Nevertheless, reproducibility across laboratories is a major concern, as discrepancies among results make comparability impractical. Aims: herein, we report preliminary results from the “Italian MM‐MRD network” project. Patients & Methods MRD in bone marrow (BM) samples have been measured from newly diagnosed MM patients using next‐generation flow‐cytometry (NGF) or next‐generation sequencing (NGS) approaches in different laboratories.
Results
The NGF workgroup (7 laboratories) implemented the Euro‐Flow Standard‐Operating‐Protocol to reach minimum 1 × 10 −5 sensitivity. The inter‐operator retrospective study (Stage 1) showed high inter‐center concordance in monoclonal plasma cells detection (ICC = 0.90, p < 0.001), whereas moderate concordance was observed in the inter‐laboratory correlation (Stage 2) in in‐vivo samples (ICC = 0.63, p < 0.001), reaching a median limit‐of‐detection (LOD) and limit‐of‐quantification (LOQ) of 8 × 10−6 and 2 × 10 −5 , respectively. Greater variability was also observed in the analysis of other BM cell populations. The NGS workgroup (4 laboratories) employed a targeted amplicon‐based approach to detect clonotypic IGH/IGK gene rearrangements in diagnostic samples, subsequently used to track MRD in mock samples. The experimental design was divided into three quality‐control (QC) rounds, focused on finding a shared strategy for clonotype identification (QC1: 100% concordance among centers), or quantifying MRD in mock samples (concordance: 81% [QC2]; 91% [QC3]). The 10 −5 ‐sensitivity level was successfully reached in most of tested dilutions (QC2: 19/20 = 95%; QC3: 19/23 = 83%).
Conclusion
Overall, this pilot study provided preliminary data for MRD harmonization across Italian centers, paving the way for an expanded network, aiming at reducing variability, improving comparability, and enabling broader use of MRD‐monitoring in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
- Division of Hematology, A O U Città Della Salute e Della Scienza di Torino, University of Torino, Turin, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
ORCID-Profile: Marina Martello, Vincenza Solli, Simona Barbato, Angelo Belotti, Francesco Buccisano, Alessandra Romano
Förderung
- Ministry of Health
Zitieren
APA
Oliva, S., Martello, M., Saraci, E., Armuzzi, S., Solli, V., Barbato, S., Belotti, A., Bolli, N., Bono, C., Buccisano, F., Chiarini, M., Irno Consalvo, M. A., Cordone, I., Drandi, D., Galimberti, S., Genuardi, E., Giustini, V., Guerrini, F., Lionetti, M., …, & Terragna, C. (2026). Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience. Cancer Medicine. https://doi.org/10.1002/cam4.71678
Vancouver
Oliva S, Martello M, Saraci E, Armuzzi S, Solli V, Barbato S, et al. Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience. Cancer Medicine. 2026. doi:10.1002/cam4.71678
BibTeX
@article{Oliva2026,
author = {Oliva, Stefania and Martello, Marina and Saraci, Elona and Armuzzi, Silvia and Solli, Vincenza and Barbato, Simona and Belotti, Angelo and Bolli, Niccolò and Bono, Clara and Buccisano, Francesco and Chiarini, Marco and Irno Consalvo, Maria Antonietta and Cordone, Iole and Drandi, Daniela and Galimberti, Sara and Genuardi, Elisa and Giustini, Viviana and Guerrini, Francesca and Lionetti, Marta and Maheda, Akihiro and Marino, Sara and Masi, Serena and Matera, Antonio and Mengarelli, Andrea and Parrinello, Nunziatina Laura and Roccaro, Aldo Maria and Romano, Alessandra and Rossi, Giovanni and Taurisano, Barbara and Tonini, Alessia and Trimarco, Valentina and Triolo, Anna Maria and Vigliotta, Ilaria and Zambello, Renato and Bruno, Benedetto and Cavo, Michele and Zamagni, Elena and Terragna, Carolina},
title = {Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71678}
}
EUVIMED